Evidence map›Paper›PMID 42034652›Full record

ArticleNPJ vaccines2026

Prefusion-stabilized SARS-CoV-2 spike reshapes antigenic hierarchy and antibody targeting against conserved and occluded epitopes.

Shintaro Oishi, Ryutaro Kotaki, Hisham M Dokainish, Saya Moriyama, Shinichiro Ota, Takayuki Matsumura, Tomohiro Takano, Taishi Onodera, Yu Adachi, Kazutaka Terahara and 5 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shintaro Oishi *Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Ryutaro Kotaki *Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan. ryutaro-kotaki@g.ecc.u-tokyo.ac.jp.
Hisham M Dokainish *Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Saya MoriyamaResearch Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Shinichiro OtaRespiratory Disease Center, Tokyo Shinagawa Hospital, Tokyo, Japan.
Takayuki MatsumuraResearch Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Tomohiro TakanoResearch Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Taishi OnoderaResearch Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Yu AdachiResearch Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Kazutaka TeraharaResearch Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Masanori IsogawaDepartment of Virology II, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Kazuhiko KatayamaLaboratory of Viral Infection Control, Department of Infection Control and Immunology, Ōmura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan.
Takashi SatoRespiratory Disease Center, Tokyo Shinagawa Hospital, Tokyo, Japan.
Masaharu ShinkaiRespiratory Disease Center, Tokyo Shinagawa Hospital, Tokyo, Japan. shinkai050169@gmail.com.
Yoshimasa TakahashiResearch Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan. takahashi.yos@jihs.go.jp.

Funding

Japan Agency for Medical Research and Development JP223fa627001Japan Agency for Medical Research and Development JP243fa627005JSPS KAKENHI JP22K16383Ministry of Health, Labour and Welfare 23HA2021RIKEN Center for Computational Science hp240149RIKEN Center for Computational Science, Japan hp230052
6 · The paper itself

Abstract

Receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike contains multiple classes of antibody epitopes that are associated with diverse neutralizing activities. Although both natural infection and vaccination robustly elicit RBD-reactive and neutralizing antibodies, the spike antigenic structures presented to the immune system may differ, leading to qualitative differences in the antibody responses. Using large and well-controlled cohorts, we show that the neutralizing potency index (NPI), calculated as the ratio of neutralizing titer to RBD IgG titer, is approximately fivefold lower in vaccine recipients than in convalescent individuals, independent of disease severity, comorbidities, or demographic factors. This reduction in NPI is associated with enhanced antibody targeting to non-neutralizing, yet conserved and structurally occluded RBD epitope. Molecular dynamics (MD) simulations together with the binding assay demonstrate that the occluded epitope is allosterically exposed by stabilizing mutations introduced into the vaccine spike antigen, a process mediated by a highly extended RBD-up conformation. Collectively, our findings demonstrate that RBD conformational modulation by stabilizing mutations shapes vaccine antigenicity and likely alters the epitope landscape of antibody responses.

Identifiers

PMID42034652
PMCPMC13324858

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.